medline.ch Onkologie Urologische Tumoren

	PARP inhibitors in metastatic prostate cancer: current evidence and future directions. Clin Adv Hematol Oncol McKendry K, Maurice-Dror C, Chi KN. PMID: 43002478 [PubMed - indexed for MEDLINE]
	Component-specific institutional learning curve of intracorporeal urinary diversion during robot-assisted radical cystectomy: a risk-adjusted cumulative sum analysis. J Robot Surg Fukata S, Ichimura N, Suzuki Y, Kohno S, Yoshimura R, Kurano Y, Shigehisa R, Atagi K, Takemori D, Shiba Y, Yamamoto S, Osakabe H, Nao T, Shimamoto T, Fukuhara H, Shimizu N, Ashida S, Karashima T, Inoue K. PMID: 43002320 [PubMed - indexed for MEDLINE]
	Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined With Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial: Erratum. J Urol Zhang S, Li T, Li D, Yin Y, Zhu W, Jiang N, Zhang S, Yang R, Guo H. PMID: 43001677 [PubMed - in process]
	Internet Access, Health-Related Internet Use, and Pelvic Floor Muscle Exercise Adherence Among Prostate Cancer Patients With Urinary Incontinence After Radical Prostatectomy: A Cross-Sectional Study. Cancer Nurs Huang H, He Y, Qu Y, Zhang L, Zhao Y, Gu C, Weng X, Li S, Gong J. PMID: 43001635 [PubMed - as supplied by publisher]
	Identification of the Glycosaminoglycan Metabolism-Related Protein IDUA Associated With Tumor Progression and Prognosis in ccRCC. Cancer Med Cao Z, Yan S, Chu W, Yuan H, Shen Z, Bi L, Peng L. PMID: 43001549 [PubMed - indexed for MEDLINE]
	Optimized pharmacotherapeutic management of immune checkpoint inhibitor treatment in metastatic clear-cell renal cell carcinoma. Expert Opin Pharmacother Sridharan K, Roviello G, Massari F, Sivaramakrishnan G, Calandrelli C, Santoni M. PMID: 43000686 [PubMed - as supplied by publisher]
	Clinical and translational profiling of oncotherad (MRB-CFI-1) nanoimmunotherapy identifies HER-2/SERBP1-associated recurrence and HABP4/IFN-Î³-associated disease control in pT1 non-muscle-invasive bladder cancer after BCG failure. J Cancer Res Clin Oncol Gonçalves JM, de Arruda Camargo GC, de Oliveira G, Caria PHF, da Silva Santos A, de Castro Roston JR, de Moraes Lacerda T, de Jesus MB, de Freitas LLL, Bottene MC, Lestingi JFP, Kobarg J, Durán N, Alonso JCC, Fávaro WJ. PMID: 43000577 [PubMed - indexed for MEDLINE]
	Prehabilitation in oncology patients, with particular emphasis on bladder cancer surgery. Support Care Cancer Nowakowski D, Ma, Majer K, Mirkiewicz W, Szarkowski K, Szkutnik-Fiedler D. PMID: 43000467 [PubMed - indexed for MEDLINE]
	Acceptability of at-home urine self-testing for bladder health problems: a qualitative study. BMC Public Health Lidington E, Schmeising-Barnes N, Goff M, Carter A, Kelly P, Knight A, Josephides E, Cumberbatch M, Sasieni P, Catto JW, Waller J. PMID: 43000298 [PubMed - indexed for MEDLINE]
	Improving the Quality of Care in Advanced Prostate Cancer Through Personalised Diagnostic Testing. Outcomes of a Sharing Progress in Cancer Care taskforce conducted under the auspices of the European Association of Urology. Crit Rev Oncol Hematol Bjartell A, Compérat E, Oldenburg J, Bonanni B, Bossi A, Briers E, Herrmann K, Van Poppel H. PMID: 43000079 [PubMed - as supplied by publisher]
	Salvage High-Dose-Rate Brachytherapy for Localized Prostate Cancer Recurrence: A Comparative Analysis of 2 Fractionation Schedules-Single-Institution Study of 223 Patients. Adv Radiat Oncol Stankiewicz M, Wilk A, Krzempek M, Kellas-, Szlag M, Wojcieszek P. PMID: 42999902 [PubMed]
	Stem Cell-Derived Extracellular Vesicles in Bladder Cancer: Diagnostic Potential and Therapeutic Challenges. Int J Nanomedicine Lu W, Fu P, Li C, Lou K, Feng S, Wang Y. PMID: 42999830 [PubMed - indexed for MEDLINE]
	Retraction notice to "Safety and Efficacy Of Sorafenib In Patients With Castrate Resistant Prostate Cancer: A Phase II Study" [Urologic Oncology: Seminars and Original Investigations 28 (2010) 21-27]. Urol Oncol Safarinejad MR. PMID: 42998955 [PubMed - as supplied by publisher]
	Enhanced image quality and interpretation efficiency of voxelwise-computed diffusion-weighted imaging for bladder cancer VI-RADS assessment. Abdom Radiol (NY) Zhang M, Chen C, Zhao Q, Zeng X, Cai W, Ma Z. PMID: 42998145 [PubMed - as supplied by publisher]
	Epigenetic reprogramming in Urothelial bladder cancer: mechanisms, biomarkers, and therapeutic opportunities. Epigenetics Yuanjiang Q, Liming Y. PMID: 42998129 [PubMed - indexed for MEDLINE]
	Navigating the current and future perioperative treatment landscape of muscle-invasive bladder cancer (MIBC). Transl Cancer Res Azad F, Kevu E, Aragon-Ching JB. PMID: 42997899 [PubMed]
	Radiomics-augmented lesion characterization on prostate multiparametric magnetic resonance imaging: first-order features and ratio metrics may improve diagnostic performance in prostate cancer. Quant Imaging Med Surg Niessen C, Haas M, Burger M, Engelmann SU, Eckl C, Vogel E, Schnabel MJ, Stroszczynski C, Weber F, Haas SL, Mayr R, Pickl C. PMID: 42997770 [PubMed]
	Prognostic value of neutrophil-to-lymphocyte ratio in renal cell carcinoma: an updated systematic review and meta-analysis. Transl Androl Urol Luo Z, Lin Z, Chen X, Kuang Z. PMID: 42997244 [PubMed]
	A transcriptomic signature of mechanical-memory-related genes predicts progression in prostate cancer. Transl Androl Urol Sun T, Wu Y, Chen H, Wang F. PMID: 42997240 [PubMed]
	Multidisciplinary management of metastatic renal cell carcinoma: a narrative review. Transl Androl Urol Fribourg-Liendo RA, Kothari A, Yip W. PMID: 42997216 [PubMed]

Artikel 1 - 20 / 182810

Seite 1 von 9141

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung